Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Jack William Lawler, Ph.D.

TitleProfessor of Pathology
InstitutionBeth Israel Deaconess Medical Center
DepartmentPathology
AddressBeth Israel Deaconess Med Ctr
Rn 270k
99 Brookline Ave
Boston MA 02215
Phone617/667-1694
Fax617/667-3591

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Duquette M, Sadow PM, Lawler J, Nucera C. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2013; 4:189.
    View in: PubMed
  2. Qin L, Zhao D, Xu J, Ren X, Terwilliger EF, Parangi S, Lawler J, Dvorak HF, Zeng H. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood. 2013 Mar 14; 121(11):2154-64.
    View in: PubMed
  3. Johnson CA, Kleshchenko YY, Ikejiani AO, Udoko AN, Cardenas TC, Pratap S, Duquette MA, Lima MF, Lawler J, Villalta F, Nde PN. Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection. PLoS One. 2012; 7(7):e40614.
    View in: PubMed
  4. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W. SCF(ß-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012 Jul 2; 209(7):1289-307.
    View in: PubMed
  5. Lynch JM, Maillet M, Vanhoutte D, Schloemer A, Sargent MA, Blair NS, Lynch KA, Okada T, Aronow BJ, Osinska H, Prywes R, Lorenz JN, Mori K, Lawler J, Robbins J, Molkentin JD. A thrombospondin-dependent pathway for a protective ER stress response. Cell. 2012 Jun 8; 149(6):1257-68.
    View in: PubMed
  6. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012 May; 2(5):a006627.
    View in: PubMed
  7. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol. 2011 Oct; 3(10):a009712.
    View in: PubMed
  8. Seymour KA, Sadowitz B, Stein JJ, Lawler J, Maier KG, Gahtan V. Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. Am J Surg. 2011 Nov; 202(5):553-7.
    View in: PubMed
  9. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A. 2011 Jun 14; 108(24):9939-44.
    View in: PubMed
  10. Olerud J, Mokhtari D, Johansson M, Christoffersson G, Lawler J, Welsh N, Carlsson PO. Thrombospondin-1: an islet endothelial cell signal of importance for ß-cell function. Diabetes. 2011 Jul; 60(7):1946-54.
    View in: PubMed
  11. Tan K, Lawler J. The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein. BMC Struct Biol. 2011; 11:22.
    View in: PubMed
  12. Cursiefen C, Maruyama K, Bock F, Saban D, Sadrai Z, Lawler J, Dana R, Masli S. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med. 2011 May 9; 208(5):1083-92.
    View in: PubMed
  13. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011 Apr 1; 71(7):2417-22.
    View in: PubMed
  14. Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, Primo L, Khosravi-Far R, Bussolino F, Rabinovitz I, Lawler J. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood. 2011 Apr 28; 117(17):4658-66.
    View in: PubMed
  15. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309.
    View in: PubMed
  16. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget. 2010 Dec; 1(8):751-6.
    View in: PubMed
  17. Ezzie ME, Piper MG, Montague C, Newland CA, Opalek JM, Baran C, Ali N, Brigstock D, Lawler J, Marsh CB. Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011 Apr; 44(4):556-61.
    View in: PubMed
  18. Lawler J. Megakaryocytes join the war on cancer. Blood. 2010 Jun 3; 115(22):4326-7.
    View in: PubMed
  19. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010 Jun 8; 107(23):10649-54.
    View in: PubMed
  20. Tan K, Lawler J. The interaction of Thrombospondins with extracellular matrix proteins. J Cell Commun Signal. 2009 Dec; 3(3-4):177-87.
    View in: PubMed
  21. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, Mulinyawe SB, Annis DS, Huberman AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, Smith SJ, Luo ZD, Rosenthal A, Mosher DF, Barres BA. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009 Oct 16; 139(2):380-92.
    View in: PubMed
  22. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009 Oct; 19(10):1077-84.
    View in: PubMed
  23. Lawler J. Introduction to the tumour microenvironment review series. J Cell Mol Med. 2009 Aug; 13(8A):1403-4.
    View in: PubMed
  24. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009 Oct; 23(10):3368-76.
    View in: PubMed
  25. Ren B, Song K, Parangi S, Jin T, Ye M, Humphreys R, Duquette M, Zhang X, Benhaga N, Lawler J, Khosravi-Far R. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res. 2009 May 1; 69(9):3856-65.
    View in: PubMed
  26. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, Bornstein P, Lawler J, Benjamin LE. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol. 2009 May; 296(5):H1344-51.
    View in: PubMed
  27. Tan K, Duquette M, Joachimiak A, Lawler J. The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding. FASEB J. 2009 Aug; 23(8):2490-501.
    View in: PubMed
  28. Velasco P, Huegel R, Brasch J, Schröder JM, Weichenthal M, Stockfleth E, Schwarz T, Lawler J, Detmar M, Lange-Asschenfeldt B. The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. J Invest Dermatol. 2009 Aug; 129(8):2022-30.
    View in: PubMed
  29. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan; 8(1):64-74.
    View in: PubMed
  30. Tan K, Duquette M, Liu JH, Lawler J, Wang JH. The crystal structure of the heparin-binding reelin-N domain of f-spondin. J Mol Biol. 2008 Sep 19; 381(5):1213-23.
    View in: PubMed
  31. Posey KL, Hankenson K, Veerisetty AC, Bornstein P, Lawler J, Hecht JT. Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol. 2008 Jun; 172(6):1664-74.
    View in: PubMed
  32. Olerud J, Johansson M, Lawler J, Welsh N, Carlsson PO. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes. 2008 Jul; 57(7):1870-7.
    View in: PubMed
  33. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat. 2009 Mar; 114(1):85-96.
    View in: PubMed
  34. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, Lawler JW, Gutierrez LS. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008; 75(1):9-21.
    View in: PubMed
  35. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008 Mar; 65(5):700-12.
    View in: PubMed
  36. Tan K, Duquette M, Liu JH, Shanmugasundaram K, Joachimiak A, Gallagher JT, Rigby AC, Wang JH, Lawler J. Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain. J Biol Chem. 2008 Feb 15; 283(7):3932-41.
    View in: PubMed
  37. Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes. 2007 Dec; 56(12):2982-9.
    View in: PubMed
  38. Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res. 2007 Jul 1; 13(13):3968-76.
    View in: PubMed
  39. Chen FH, Herndon ME, Patel N, Hecht JT, Tuan RS, Lawler J. Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem. 2007 Aug 24; 282(34):24591-8.
    View in: PubMed
  40. Budhani F, Leonard KA, Bergdahl A, Gao J, Lawler J, Davis EC. Vascular response to intra-arterial injury in the thrombospondin-1 null mouse. J Mol Cell Cardiol. 2007 Aug; 43(2):210-4.
    View in: PubMed
  41. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res. 2007 Sep-Nov; 74(2-3):90-9.
    View in: PubMed
  42. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol. 2007 Mar; 210(3):807-18.
    View in: PubMed
  43. Zhang X, Connolly C, Duquette M, Lawler J, Parangi S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett. 2007 Mar 8; 247(1):143-9.
    View in: PubMed
  44. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood. 2006 Aug 15; 108(4):1280-3.
    View in: PubMed
  45. Yee KO, Connolly CM, Pines M, Lawler J. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther. 2006 Feb; 5(2):218-24.
    View in: PubMed
  46. Tan K, Duquette M, Liu JH, Zhang R, Joachimiak A, Wang JH, Lawler J. The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. Structure. 2006 Jan; 14(1):33-42.
    View in: PubMed
  47. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006 Apr; 1765(2):178-88.
    View in: PubMed
  48. Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood. 2006 Feb 1; 107(3):955-64.
    View in: PubMed
  49. Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005 Aug 1; 11(15):5622-30.
    View in: PubMed
  50. Chen FH, Thomas AO, Hecht JT, Goldring MB, Lawler J. Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J Biol Chem. 2005 Sep 23; 280(38):32655-61.
    View in: PubMed
  51. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005 Jun 7; 111(22):2935-42.
    View in: PubMed
  52. Ludlow A, Yee KO, Lipman R, Bronson R, Weinreb P, Huang X, Sheppard D, Lawler J. Characterization of integrin beta6 and thrombospondin-1 double-null mice. J Cell Mol Med. 2005 Apr-Jun; 9(2):421-37.
    View in: PubMed
  53. Saumet A, Slimane MB, Lanotte M, Lawler J, Dubernard V. Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood. 2005 Jul 15; 106(2):658-67.
    View in: PubMed
  54. Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ, Frazier WA, Roberts DD. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol. 2005 Apr; 24(2):110-23.
    View in: PubMed
  55. Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005 Mar 15; 11(6):2337-44.
    View in: PubMed
  56. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A. 2005 Feb 22; 102(8):2934-9.
    View in: PubMed
  57. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005 Feb 14; 168(4):643-53.
    View in: PubMed
  58. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005 Feb 11; 120(3):421-33.
    View in: PubMed
  59. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005 Jan; 7(1):101-11.
    View in: PubMed
  60. Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J, Mosher DF, Roberts DD. Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem. 2004 Oct 1; 279(40):41734-43.
    View in: PubMed
  61. Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol. 2004 Aug; 165(2):541-52.
    View in: PubMed
  62. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol. 2004 Jun; 36(6):1038-45.
    View in: PubMed
  63. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004 Jun; 36(6):961-8.
    View in: PubMed
  64. Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, Benjamin LE. Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther. 2004 Apr; 3(4):402-5.
    View in: PubMed
  65. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004 Apr; 45(4):1117-24.
    View in: PubMed
  66. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004 Mar 1; 64(5):1570-4.
    View in: PubMed
  67. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem. 2004 Mar 1; 91(4):766-76.
    View in: PubMed
  68. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem. 2004 May 14; 279(20):21439-48.
    View in: PubMed
  69. Hochegger K, Knight S, Hugo C, Mayer G, Lawler J, Mayadas TN, Rosenkranz AR. Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. Nephron Exp Nephrol. 2004; 96(2):e31-8.
    View in: PubMed
  70. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn. 2003 Dec; 228(4):630-42.
    View in: PubMed
  71. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12917-22.
    View in: PubMed
  72. Kipnes J, Carlberg AL, Loredo GA, Lawler J, Tuan RS, Hall DJ. Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro. Osteoarthritis Cartilage. 2003 Jun; 11(6):442-54.
    View in: PubMed
  73. Lee T, Nesselroth SM, Olson ET, Esemuede N, Lawler J, Sumpio BE, Gahtan V. Thrombospondin-1-induced vascular smooth muscle cell chemotaxis: the role of the type 3 repeat and carboxyl terminal domains. J Cell Biochem. 2003 Jun 1; 89(3):500-6.
    View in: PubMed
  74. Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ. Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis. 2003 Feb; 24(2):199-207.
    View in: PubMed
  75. Yee KO, Duquette M, Ludlow A, Lawler J. Purification and analysis of thrombospondin-1. Curr Protoc Cell Biol. 2003 Feb; Chapter 10:Unit 10.10.
    View in: PubMed
  76. Yano K, Brown LF, Lawler J, Miyakawa T, Detmar M. Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J Invest Dermatol. 2003 Jan; 120(1):14-9.
    View in: PubMed
  77. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol. 2002 Oct 28; 159(2):373-82.
    View in: PubMed
  78. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol. 2002 Sep; 161(3):831-9.
    View in: PubMed
  79. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002 Jan-Mar; 6(1):1-12.
    View in: PubMed
  80. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol. 2001 Nov; 159(5):1949-56.
    View in: PubMed
  81. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 2001 Nov 1; 61(21):7830-9.
    View in: PubMed
  82. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001 Oct 23; 98(22):12485-90.
    View in: PubMed
  83. Miao WM, Vasile E, Lane WS, Lawler J. CD36 associates with CD9 and integrins on human blood platelets. Blood. 2001 Mar 15; 97(6):1689-96.
    View in: PubMed
  84. Nesselroth SM, Willis AI, Fuse S, Olson ET, Lawler J, Sumpio BE, Gahtan V. The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. J Vasc Surg. 2001 Mar; 33(3):595-600.
    View in: PubMed
  85. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001 Jan; 21(1):47-54.
    View in: PubMed
  86. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000 Dec; 19(7):597-614.
    View in: PubMed
  87. Hofsteenge J, Huwiler KG, Macek B, Hess D, Lawler J, Mosher DF, Peter-Katalinic J. C-mannosylation and O-fucosylation of the thrombospondin type 1 module. J Biol Chem. 2001 Mar 2; 276(9):6485-98.
    View in: PubMed
  88. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000 Oct; 12(5):634-40.
    View in: PubMed
  89. Majluf-Cruz A, Manns JM, Uknis AB, Yang X, Colman RW, Harris RB, Frazier W, Lawler J, DeLa Cadena RA. Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays. J Lab Clin Med. 2000 Oct; 136(4):292-302.
    View in: PubMed
  90. Chen H, Deere M, Hecht JT, Lawler J. Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes. J Biol Chem. 2000 Aug 25; 275(34):26538-44.
    View in: PubMed
  91. Abdelouahed M, Ludlow A, Brunner G, Lawler J. Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1. J Biol Chem. 2000 Jun 16; 275(24):17933-6.
    View in: PubMed
  92. Newton G, Weremowicz S, Morton CC, Jenkins NA, Gilbert DJ, Copeland NG, Lawler J. The thrombospondin-4 gene. Mamm Genome. 1999 Oct; 10(10):1010-6.
    View in: PubMed
  93. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 1999 Sep 28; 100(13):1423-31.
    View in: PubMed
  94. Sipes JM, Krutzsch HC, Lawler J, Roberts DD. Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation. J Biol Chem. 1999 Aug 6; 274(32):22755-62.
    View in: PubMed
  95. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol. 1999 Aug; 155(2):441-52.
    View in: PubMed
  96. Eda S, Lawler J, Sherman IW. Plasmodium falciparum-infected erythrocyte adhesion to the type 3 repeat domain of thrombospondin-1 is mediated by a modified band 3 protein. Mol Biochem Parasitol. 1999 May 25; 100(2):195-205.
    View in: PubMed
  97. Tucker RP, Hagios C, Chiquet-Ehrismann R, Lawler J, Hall RJ, Erickson CA. Thrombospondin-1 and neural crest cell migration. Dev Dyn. 1999 Apr; 214(4):312-22.
    View in: PubMed
  98. Hecht JT, Montufar-Solis D, Decker G, Lawler J, Daniels K, Duke PJ. Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. Matrix Biol. 1998 Dec; 17(8-9):625-33.
    View in: PubMed
  99. Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R, Clezardin P. CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochem Funct. 1998 Sep; 16(3):211-21.
    View in: PubMed
  100. Adams JC, Seed B, Lawler J. Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1. EMBO J. 1998 Sep 1; 17(17):4964-74.
    View in: PubMed
  101. Hecht JT, Deere M, Putnam E, Cole W, Vertel B, Chen H, Lawler J. Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Matrix Biol. 1998 Aug; 17(4):269-78.
    View in: PubMed
  102. Guo N, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, Roberts DD. Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res. 1998 Jul 15; 58(14):3154-62.
    View in: PubMed
  103. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998 Jun 26; 93(7):1159-70.
    View in: PubMed
  104. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A. 1998 May 26; 95(11):6343-8.
    View in: PubMed
  105. Urry LA, Whittaker CA, Duquette M, Lawler J, DeSimone DW. Thrombospondins in early Xenopus embryos: dynamic patterns of expression suggest diverse roles in nervous system, notochord, and muscle development. Dev Dyn. 1998 Apr; 211(4):390-407.
    View in: PubMed
  106. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998 Mar 1; 101(5):982-92.
    View in: PubMed
  107. Riessen R, Kearney M, Lawler J, Isner JM. Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J. 1998 Feb; 135(2 Pt 1):357-64.
    View in: PubMed
  108. Merle B, Malaval L, Lawler J, Delmas P, Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem. 1997 Oct 1; 67(1):75-83.
    View in: PubMed
  109. Tucker RP, Hagios C, Chiquet-Ehrismann R, Lawler J. In situ localization of thrombospondin-1 and thrombospondin-3 transcripts in the avian embryo. Dev Dyn. 1997 Mar; 208(3):326-37.
    View in: PubMed
  110. Clezardin P, Lawler J, Amiral J, Quentin G, Delmas P. Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. Biochem J. 1997 Feb 1; 321 ( Pt 3):819-27.
    View in: PubMed
  111. Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer. 1996 Dec; 32A(14):2394-400.
    View in: PubMed
  112. Incardona F, Lawler J, Cataldo D, Panet A, Legrand Y, Foidart JM, Legrand C. Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells. J Cell Biochem. 1996 Sep 15; 62(4):431-42.
    View in: PubMed
  113. Higazi AA, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, McCrae KR, Kounnas MZ, Strickland DK, Preissner KT, Lawler J, Cines DB. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood. 1996 Jul 15; 88(2):542-51.
    View in: PubMed
  114. Rabhi-Sabile S, Pidard D, Lawler J, Renesto P, Chignard M, Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett. 1996 May 13; 386(1):82-6.
    View in: PubMed
  115. Tucker RP, Adams JC, Lawler J. Thrombospondin-4 is expressed by early osteogenic tissues in the chick embryo. Dev Dyn. 1995 Aug; 203(4):477-90.
    View in: PubMed
  116. Qabar A, Derick L, Lawler J, Dixit V. Thrombospondin 3 is a pentameric molecule held together by interchain disulfide linkage involving two cysteine residues. J Biol Chem. 1995 May 26; 270(21):12725-9.
    View in: PubMed
  117. Lawler J, McHenry K, Duquette M, Derick L. Characterization of human thrombospondin-4. J Biol Chem. 1995 Feb 10; 270(6):2809-14.
    View in: PubMed
  118. Newton G, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Lawler J. Characterization of human and mouse cartilage oligomeric matrix protein. Genomics. 1994 Dec; 24(3):435-9.
    View in: PubMed
  119. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem. 1994 Oct 28; 269(43):26783-8.
    View in: PubMed
  120. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J. 1994 Sep; 8(12):929-38.
    View in: PubMed
  121. Adamson GJ, Gellman H, Brumfield RH, Kuschner SH, Lawler JW. Flexible implant resection arthroplasty of the proximal interphalangeal joint in patients with systemic inflammatory arthritis. J Hand Surg Am. 1994 May; 19(3):378-84.
    View in: PubMed
  122. Adams JC, Lawler J. Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. Mol Biol Cell. 1994 Apr; 5(4):423-37.
    View in: PubMed
  123. Qabar AN, Lin Z, Wolf FW, O'Shea KS, Lawler J, Dixit VM. Thrombospondin 3 is a developmentally regulated heparin binding protein. J Biol Chem. 1994 Jan 14; 269(2):1262-9.
    View in: PubMed
  124. Ketis NV, Lawler J, Bendena WG. Extracellular matrix components affect the pattern of protein synthesis of endothelial cells responding to hyperthermia. In Vitro Cell Dev Biol Anim. 1993 Oct; 29A(10):768-72.
    View in: PubMed
  125. Lawler J, Duquette M, Urry L, McHenry K, Smith TF. The evolution of the thrombospondin gene family. J Mol Evol. 1993 Jun; 36(6):509-16.
    View in: PubMed
  126. San Antonio JD, Slover J, Lawler J, Karnovsky MJ, Lander AD. Specificity in the interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin. Biochemistry. 1993 May 11; 32(18):4746-55.
    View in: PubMed
  127. Adams JC, Lawler J. Diverse mechanisms for cell attachment to platelet thrombospondin. J Cell Sci. 1993 Apr; 104 ( Pt 4):1061-71.
    View in: PubMed
  128. Adams J, Lawler J. Extracellular matrix: the thrombospondin family. Curr Biol. 1993 Mar; 3(3):188-90.
    View in: PubMed
  129. Lawler J, Duquette M, Whittaker CA, Adams JC, McHenry K, DeSimone DW. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol. 1993 Feb; 120(4):1059-67.
    View in: PubMed
  130. Legrand C, Thibert V, Dubernard V, Bégault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. Blood. 1992 Apr 15; 79(8):1995-2003.
    View in: PubMed
  131. Corless CL, Mendoza A, Collins T, Lawler J. Colocalization of thrombospondin and syndecan during murine development. Dev Dyn. 1992 Apr; 193(4):346-58.
    View in: PubMed
  132. Lawler J, Ferro P, Duquette M. Expression and mutagenesis of thrombospondin. Biochemistry. 1992 Feb 4; 31(4):1173-80.
    View in: PubMed
  133. Lawler J, Duquette M, Ferro P, Copeland NG, Gilbert DJ, Jenkins NA. Characterization of the murine thrombospondin gene. Genomics. 1991 Nov; 11(3):587-600.
    View in: PubMed
  134. Lawler J, Duquette M, Ferro P. Cloning and sequencing of chicken thrombospondin. J Biol Chem. 1991 May 5; 266(13):8039-43.
    View in: PubMed
  135. Ketis NV, Lawler J. Effects of thrombospondin antibody on the recovery of endothelial cells from hyperthermia. J Cell Sci. 1990 Jun; 96 ( Pt 2):263-70.
    View in: PubMed
  136. Coetzer T, Palek J, Lawler J, Liu SC, Jarolim P, Lahav M, Prchal JT, Wang W, Alter BP, Schewitz G, et al. Structural and functional heterogeneity of alpha spectrin mutations involving the spectrin heterodimer self-association site: relationships to hematologic expression of homozygous hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood. 1990 Jun 1; 75(11):2235-44.
    View in: PubMed
  137. Sherwood JA, Roberts DD, Spitalnik SL, Lawler JW, Miller LH, Howard RJ. Falciparum malaria parasitized erythrocytes bind to a carboxy-terminal thrombospondin fragment and not the amino-terminal heparin-binding region. Mol Biochem Parasitol. 1990 May; 40(2):173-81.
    View in: PubMed
  138. Lambert S, Yu H, Prchal JT, Lawler J, Ruff P, Speicher D, Cheung MC, Kan YW, Palek J. cDNA sequence for human erythrocyte ankyrin. Proc Natl Acad Sci U S A. 1990 Mar; 87(5):1730-4.
    View in: PubMed
  139. Korsgren C, Lawler J, Lambert S, Speicher D, Cohen CM. Complete amino acid sequence and homologies of human erythrocyte membrane protein band 4.2. Proc Natl Acad Sci U S A. 1990 Jan; 87(2):613-7.
    View in: PubMed
  140. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood. 1989 Nov 1; 74(6):2022-7.
    View in: PubMed
  141. Jarolim P, Palek J, Coetzer TL, Lawler J, Velez-Garcia E, Fradera J, Charles A, Jacob HS, Moake JL. Severe hemolysis and red cell fragmentation caused by the combination of a spectrin mutation with a thrombotic microangiopathy. Am J Hematol. 1989 Sep; 32(1):50-6.
    View in: PubMed
  142. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989 Jul 14; 58(1):95-101.
    View in: PubMed
  143. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol. 1988 Dec; 107(6 Pt 1):2351-61.
    View in: PubMed
  144. Lawler J, Coetzer TL, Mankad VN, Moore RB, Prchal JT, Palek J. Spectrin-alpha I/61: a new structural variant of alpha-spectrin in a double-heterozygous form of hereditary pyropoikilocytosis. Blood. 1988 Oct; 72(4):1412-5.
    View in: PubMed
  145. Dainiak N, Warren HB, Kreczko S, Riordan MA, Feldman L, Lawler J, Cohen AM, Davies PF. Acetylated lipoproteins impair erythroid growth factor release from endothelial cells. J Clin Invest. 1988 Mar; 81(3):834-43.
    View in: PubMed
  146. Ketis NV, Lawler J, Hoover RL, Karnovsky MJ. Effects of heat shock on the expression of thrombospondin by endothelial cells in culture. J Cell Biol. 1988 Mar; 106(3):893-904.
    View in: PubMed
  147. Coetzer TL, Lawler J, Liu SC, Prchal JT, Gualtieri RJ, Brain MC, Dacie JV, Palek J. Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis. N Engl J Med. 1988 Jan 28; 318(4):230-4.
    View in: PubMed
  148. Cohen AM, Liu SC, Lawler J, Derick L, Palek J. Identification of the protein 4.1 binding site to phosphatidylserine vesicles. Biochemistry. 1988 Jan 26; 27(2):614-9.
    View in: PubMed
  149. Coetzer T, Lawler J, Prchal JT, Palek J. Molecular determinants of clinical expression of hereditary elliptocytosis and pyropoikilocytosis. Blood. 1987 Sep; 70(3):766-72.
    View in: PubMed
  150. Clezardin P, Hunter NR, Lawler J, Dawes J, McGregor JL. Production, characterization, and use of monoclonal antibodies directed against human blood platelet thrombospondin: immunologic comparison with human endothelial and fibroblast thrombospondins. Semin Thromb Hemost. 1987 Jul; 13(3):261-75.
    View in: PubMed
  151. Lawler J, Hynes RO. Structural organization of the thrombospondin molecule. Semin Thromb Hemost. 1987 Jul; 13(3):245-54.
    View in: PubMed
  152. Sloand EM, Kenney DM, Chao FC, Lawler J, Tullis JL. Platelet antithrombin defect in malignancy: platelet protein alterations. Blood. 1987 Feb; 69(2):479-85.
    View in: PubMed
  153. Lawler J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol. 1986 Nov; 103(5):1635-48.
    View in: PubMed
  154. Clezardin P, Hunter NR, Lawler JW, Pratt DA, McGregor JL, Pepper DS, Dawes J. Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. Eur J Biochem. 1986 Sep 15; 159(3):569-79.
    View in: PubMed
  155. Lawler J. The structural and functional properties of thrombospondin. Blood. 1986 May; 67(5):1197-209.
    View in: PubMed
  156. Lawler J, Cohen AM, Chao FC, Moriarty DJ. Thrombospondin in essential thrombocythemia. Blood. 1986 Feb; 67(2):555-8.
    View in: PubMed
  157. Lawler J, Connolly JE, Ferro P, Derick LH. Thrombin and chymotrypsin interactions with thrombospondin. Ann N Y Acad Sci. 1986; 485:273-87.
    View in: PubMed
  158. Dainiak N, Kreczko S, Cohen A, Pannell R, Lawler J. Primary human marrow cultures for erythroid bursts in a serum-substituted system. Exp Hematol. 1985 Nov; 13(10):1073-9.
    View in: PubMed
  159. Liu SC, Zhai S, Lawler J, Palek J. Hemin-mediated dissociation of erythrocyte membrane skeletal proteins. J Biol Chem. 1985 Oct 5; 260(22):12234-9.
    View in: PubMed
  160. Lawler J, Coetzer TL, Palek J, Jacob HS, Luban N. Sp alpha I/65: a new variant of the alpha subunit of spectrin in hereditary elliptocytosis. Blood. 1985 Sep; 66(3):706-9.
    View in: PubMed
  161. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. The structure of human platelet thrombospondin. J Biol Chem. 1985 Mar 25; 260(6):3762-72.
    View in: PubMed
  162. Lahav J, Lawler J, Gimbrone MA. Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition in binding. Eur J Biochem. 1984 Nov 15; 145(1):151-6.
    View in: PubMed
  163. Lawler J, Liu SC, Palek J, Prchal J. A molecular defect of spectrin in a subset of patients with hereditary elliptocytosis. Alterations in the alpha-subunit domain involved in spectrin self-association. J Clin Invest. 1984 Jun; 73(6):1688-95.
    View in: PubMed
  164. Lawler J, Liu SC, Street A, Palek J. Abnormalities in spectrin structure and function in hereditary pyropoikilocytosis and hereditary elliptocytosis. Prog Clin Biol Res. 1984; 159:191-204.
    View in: PubMed
  165. Lawler J, Palek J, Liu SC, Prchal J, Butler WM. Molecular heterogeneity of hereditary pyropoikilocytosis: identification of a second variant of the spectrin alpha-subunit. Blood. 1983 Dec; 62(6):1182-9.
    View in: PubMed
  166. Lawler J, Simons ER. Cooperative binding of calcium to thrombospondin. The effect of calcium on the circular dichroism and limited tryptic digestion of thrombospondin. J Biol Chem. 1983 Oct 25; 258(20):12098-101.
    View in: PubMed
  167. Dainiak N, Davies G, Kalmanti M, Lawler J, Kulkarni V. Platelet-derived growth factor promotes proliferation of erythropoietic progenitor cells in vitro. J Clin Invest. 1983 May; 71(5):1206-14.
    View in: PubMed
  168. Lawler J, Liu SC, Palek J, Prchal J. Molecular defect of spectrin in hereditary pyropoikilocytosis. Alterations in the trypsin-resistant domain involved in spectrin self-association. J Clin Invest. 1982 Nov; 70(5):1019-30.
    View in: PubMed
  169. Lawler J, Chao FC, Cohen CM. Evidence for calcium-sensitive structure in platelet thrombospondin. Isolation and partial characterization of thrombospondin in the presence of calcium. J Biol Chem. 1982 Oct 25; 257(20):12257-65.
    View in: PubMed
  170. Margossian SS, Lawler JW, Slayter HS. Physical characterization of platelet thrombospondin. J Biol Chem. 1981 Jul 25; 256(14):7495-500.
    View in: PubMed
  171. Lawler JW, Slayter HS. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin. Thromb Res. 1981 May 1; 22(3):267-79.
    View in: PubMed
  172. Lawler JW. Prediction of the secondary structure of platelet factor 4 and beta-thromboglobulin from their amino acid sequences. Thromb Res. 1981 Jan 1-15; 21(1-2):121-7.
    View in: PubMed
  173. Lawler JW, Chao FC, Fang PH. The effect of ultraviolet light on platelets: platelet activation and inhibition of thrombin-mediated functions. Thromb Res. 1979 Feb-Mar; 14(2-3):489-94.
    View in: PubMed
  174. Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem. 1978 Dec 10; 253(23):8609-16.
    View in: PubMed
  175. Lawler JW, Chao FC, Fang PH. Observation of a high molecular weight platelet protein released by thrombin. Thromb Haemost. 1977 Apr 30; 37(2):355-7.
    View in: PubMed
  176. Chao FC, Tullis JL, Conneely GS, Lawler JW. Aggregation of platelets and inert particles induced by thrombin. Thromb Haemost. 1976 Jun 30; 35(3):717-36.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Lawler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_